Stocks
Amylyx Pharmaceuticals Financial Statements (AMLX) |
||||||||||
| Amylyx Pharmaceuticalssmart-lab.ru | % | 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 09.11.2023 | 22.02.2024 | 09.05.2024 | 08.08.2024 | 07.11.2024 | 07.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 102.7 | 108.4 | 88.6 | 1.02 | 0.416 | 198.5 | |||
| Operating Income, bln rub | 18.7 | 1.93 | -122.1 | -53.4 | -75.7 | -249.3 | ||||
| EBITDA, bln rub | ? | 19.0 | 2.24 | -121.8 | -53.2 | -39.2 | -212.0 | |||
| Net profit, bln rub | ? | 20.9 | 4.73 | -118.8 | -72.7 | -72.7 | -259.5 | |||
| OCF, bln rub | ? | -5.17 | 13.6 | -0.489 | -66.6 | -41.6 | -95.1 | |||
| CAPEX, bln rub | ? | 0.357 | 0.356 | 0.067 | 0.089 | 0.019 | 0.531 | |||
| FCF, bln rub | ? | -5.53 | 13.2 | -0.556 | -66.7 | -41.6 | -95.6 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 78.8 | 97.2 | 94.1 | 44.8 | 75.3 | 311.3 | ||||
| Cost of production, bln rub | 5.22 | 9.36 | 116.7 | 7.63 | 0.809 | 134.5 | ||||
| R&D, bln rub | 30.0 | 44.9 | 36.3 | 23.1 | 21.2 | 125.6 | ||||
| Interest expenses, bln rub | 0.000 | 3.46 | 0.000 | 0.000 | 0.000 | 3.46 | ||||
| Assets, bln rub | 466.6 | 517.5 | 417.5 | 332.2 | 250.7 | 250.7 | ||||
| Net Assets, bln rub | ? | 418.4 | 433.4 | 324.4 | 261.3 | 196.2 | 196.2 | |||
| Debt, bln rub | 4.77 | 4.24 | 3.69 | 3.14 | 2.57 | 2.57 | ||||
| Cash, bln rub | 355.0 | 371.4 | 373.3 | 309.8 | 234.4 | 234.4 | ||||
| Net debt, bln rub | -350.3 | -367.1 | -369.6 | -306.7 | -231.8 | -231.8 | ||||
| Ordinary share price, rub | 18.3 | 14.7 | 2.84 | 1.90 | 3.24 | |||||
| Number of ordinary shares, mln | 67.4 | 67.4 | 67.9 | 68.0 | 68.1 | 68.1 | ||||
| Market cap, bln rub | 1 234 | 992 | 193 | 129 | 221 | 0 | ||||
| EV, bln rub | ? | 884 | 625 | -177 | -177 | -11 | -232 | |||
| Book value, bln rub | 418 | 433 | 324 | 261 | 196 | 196 | ||||
| EPS, rub | ? | 0.31 | 0.07 | -1.75 | -1.07 | -1.07 | -3.81 | |||
| FCF/share, rub | -0.08 | 0.20 | -0.01 | -0.98 | -0.61 | -1.40 | ||||
| BV/share, rub | 6.21 | 6.43 | 4.78 | 3.84 | 2.88 | 2.88 | ||||
| EBITDA margin, % | ? | 18.5% | 2.06% | -137.4% | -5 203% | -9 432% | -106.8% | |||
| Net margin, % | ? | 20.3% | 4.36% | -134.0% | -7 107% | -17 477% | -130.7% | |||
| FCF yield, % | ? | -4.28% | 1.08% | 8.01% | -46.1% | -43.3% | ||||
| ROE, % | ? | 0.44% | 11.4% | -21.9% | -63.5% | -132.2% | -132.2% | |||
| ROA, % | ? | 0.39% | 9.52% | -17.0% | -49.9% | -103.5% | -103.5% | |||
| P/E | ? | 672.3 | 20.1 | -2.71 | -0.78 | -0.85 | 0 | |||
| P/FCF | -23.4 | 92.9 | 12.5 | -2.17 | -2.31 | 0 | ||||
| P/S | ? | 4.20 | 2.61 | 0.48 | 0.43 | 1.12 | 0 | |||
| P/BV | ? | 2.95 | 2.29 | 0.59 | 0.49 | 1.12 | 0 | |||
| EV/EBITDA | ? | -123.8 | 15.8 | 2.21 | 1.15 | 0.05 | 1.09 | |||
| Debt/EBITDA | 49.0 | -9.25 | 4.62 | 1.99 | 1.09 | 1.09 | ||||
| R&D/CAPEX, % | 8 414% | 12 616% | 54 169% | 25 999% | 111 774% | 23 650% | ||||
| CAPEX/Revenue, % | 0.35% | 0.33% | 0.08% | 8.70% | 4.57% | 0.27% | ||||
| Amylyx Pharmaceuticals shareholders | ||||||||||
